Overview

Neoadjuvant Therapy of Pembrolizumab + Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer (EAST ENERGY)

Status:
Recruiting
Trial end date:
2025-11-30
Target enrollment:
Participant gender:
Summary
The efficacy and safety of the neoadjuvant therapy of pembrolizumab+ ramucirumab
Phase:
Phase 2
Details
Lead Sponsor:
Masahiro Tsuboi
Collaborators:
Eli Lilly and Company
Merck Sharp & Dohme Corp.
Treatments:
Pembrolizumab
Ramucirumab